Catecholamines

Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease

Retrieved on: 
Tuesday, June 29, 2021

We also expect to start an exploratory Phase 2 study with dipraglurant in blepharospasm patients in the coming months.

Key Points: 
  • We also expect to start an exploratory Phase 2 study with dipraglurant in blepharospasm patients in the coming months.
  • In a Phase 2a study dipraglurant met its primary endpoint by being generally well tolerated and showing no clinically significant safety issues.
  • However, the development of dyskinesia which may be associated with long-term use of levodopa can become as disabling as the symptoms of Parkinson's disease.
  • Addexs lead product candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM) is in a pivotal registration clinical trial for Parkinsons disease levodopa induced dyskinesia (PD-LID).

Survey data detailing impact of OFF time and dyskinesia in people affected by Parkinson’s disease presented at American Academy of Neurology (AAN) Annual Meeting

Retrieved on: 
Monday, April 19, 2021

\xe2\x80\x9cMany people experience significant disruption in their daily activities due to OFF and dyskinesia.

Key Points: 
  • \xe2\x80\x9cMany people experience significant disruption in their daily activities due to OFF and dyskinesia.
  • As a result, patients will often withdraw from social activities and experience a more significant emotional impact than we may realize.
  • \xe2\x80\x9cThese data highlight the widespread burden and impact of OFF and dyskinesia in daily living.
  • The primary treatment for PD is with levodopa; however, over time levodopa may lead to involuntary, uncontrolled movements known as dyskinesia.

Adamas Announces Two Presentations for the American Academy of Neurology 73rd Annual Meeting

Retrieved on: 
Thursday, April 15, 2021

b'Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Meeting.

Key Points: 
  • b'Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced two posters will be presented at the American Academy of Neurology (AAN) 73rd Annual Meeting.
  • \xe2\x80\x9cWe will present new data analyses of our pivotal trials evaluating the treatment impact of GOCOVRI in increasing ON time without any dyskinesia.
  • The primary treatment for PD is with levodopa; however, over time levodopa may lead to involuntary, uncontrolled movements known as dyskinesia.
  • We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.

Celebrity Chef Zarela Martinez Partners with Acorda Therapeutics on the launch of “A Taste for Life with Zarela℠”

Retrieved on: 
Monday, April 12, 2021

b"Culinary icon Zarela Martinez and Acorda Therapeutics (NASDAQ: ACOR) have partnered to launch \xe2\x80\x9cA Taste for Life with Zarela\xe2\x80\x9d to celebrate Parkinson\xe2\x80\x99s Awareness Month.

Key Points: 
  • b"Culinary icon Zarela Martinez and Acorda Therapeutics (NASDAQ: ACOR) have partnered to launch \xe2\x80\x9cA Taste for Life with Zarela\xe2\x80\x9d to celebrate Parkinson\xe2\x80\x99s Awareness Month.
  • Since then, she\xe2\x80\x99s authored three cookbooks and hosted her own show on PBS, elevating her to celebrity status.
  • In addition to her medications, she stayed socially active and used nutrition and exercise to help control her Parkinson\xe2\x80\x99s symptoms.
  • It is a prescription medicine used for the return of Parkinson\xe2\x80\x99s symptoms (known as OFF episodes) in adults treated with carbidopa/levodopa medicine.

Parkinson 's disease Market Will Reflect Significant Growth Prospects During the Study Period [2018-2030], Anticipates DelveInsight

Retrieved on: 
Wednesday, April 14, 2021

b'LAS VEGAS, April 14, 2021 /PRNewswire/ -- DelveInsight\'s " Parkinson\'s Disease Market " report provides a thorough comprehension of the Parkinson\'s Disease, historical and forecasted epidemiology, and the Parkinson\'s Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan].

Key Points: 
  • b'LAS VEGAS, April 14, 2021 /PRNewswire/ -- DelveInsight\'s " Parkinson\'s Disease Market " report provides a thorough comprehension of the Parkinson\'s Disease, historical and forecasted epidemiology, and the Parkinson\'s Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan].
  • In 2020, the US accounted for 38.36% of the total diagnosed prevalent cases of Parkinson\'s Disease in the 7MM.
  • Levodopa with a DOPA decarboxylase inhibitor is mostly a first-line treatment option for Parkinson\'s Disease .\nFor advanced Parkinson\'s Disease patients, mostly surgeries are preferred.
  • Most of the treatments are aimed at benefiting the tremor or rigidity that emerges from the disease.

Parkinson 's disease Market Will Reflect Significant Growth Prospects During the Study Period [2018-2030], Anticipates DelveInsight

Retrieved on: 
Wednesday, April 14, 2021

b'LAS VEGAS, April 14, 2021 /PRNewswire/ -- DelveInsight\'s " Parkinson\'s Disease Market " report provides a thorough comprehension of the Parkinson\'s Disease, historical and forecasted epidemiology, and the Parkinson\'s Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan].

Key Points: 
  • b'LAS VEGAS, April 14, 2021 /PRNewswire/ -- DelveInsight\'s " Parkinson\'s Disease Market " report provides a thorough comprehension of the Parkinson\'s Disease, historical and forecasted epidemiology, and the Parkinson\'s Disease market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan].
  • In 2020, the US accounted for 38.36% of the total diagnosed prevalent cases of Parkinson\'s Disease in the 7MM.
  • Levodopa with a DOPA decarboxylase inhibitor is mostly a first-line treatment option for Parkinson\'s Disease .\nFor advanced Parkinson\'s Disease patients, mostly surgeries are preferred.
  • Most of the treatments are aimed at benefiting the tremor or rigidity that emerges from the disease.

Adamas publishes new data analyses demonstrating GOCOVRI treatment more than doubled ON time without dyskinesia in patients with Parkinson’s disease

Retrieved on: 
Monday, March 29, 2021

GOCOVRI (amantadine) extended release capsules is the first and only medicine approved as a treatment both for dyskinesia in patients with Parkinsons disease (PD) receiving levodopa-based therapy and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing OFF episodes.

Key Points: 
  • GOCOVRI (amantadine) extended release capsules is the first and only medicine approved as a treatment both for dyskinesia in patients with Parkinsons disease (PD) receiving levodopa-based therapy and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing OFF episodes.
  • The publication examined data from two pivotal, placebo-controlled Phase 3 clinical studies evaluating a total of 196 patients.
  • Typically, PD clinical trials for the treatment of motor complications differentiate dyskinesia into troublesome and non- troublesome categories.
  • This analysis is unique in evaluating treatment impact by measuring the increase in ON time without any dyskinesia.

Insights on the Parkinson's Disease Treatment Global Market to 2027 - Featuring AbbVie, Acadia and GSK Among Others

Retrieved on: 
Tuesday, March 16, 2021

DUBLIN, March 16, 2021 /PRNewswire/ -- The "Parkinson's Disease Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 16, 2021 /PRNewswire/ -- The "Parkinson's Disease Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Levodopa / Carbidopa, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$ 2.5 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 9.6% CAGR
    The Parkinson's Disease Treatment market in the U.S. is estimated at US$ 1.3 Billion in the year 2020.
  • In the global MAO-Inhibitors segment, USA, Canada, Japan, China and Europe will drive the 5.6% CAGR estimated for this segment.

$4.9 Billion Worldwide Parkinson's Disease Treatment Industry to 2027 - Impact of COVID-19 on the Market - ResearchAndMarkets.com

Retrieved on: 
Monday, March 15, 2021

The "Parkinson's Disease Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parkinson's Disease Treatment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Amid the COVID-19 crisis, the global market for Parkinson's Disease Treatment estimated at US$ 4.9 Billion in the year 2020, is projected to reach a revised size of US$ 7.2 Billion by 2027, growing at a CAGR of 5.8% over the analysis period 2020-2027.
  • Levodopa / Carbidopa, one of the segments analyzed in the report, is projected to record a 6.9% CAGR and reach US$ 2.5 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $1.3 Billion, While China is Forecast to Grow at 9.6% CAGR
    The Parkinson's Disease Treatment market in the U.S. is estimated at US$ 1.3 Billion in the year 2020.

IRICoR, Université de Montréal, IRIC and Valence Discovery collaborate to design novel drug candidates for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients

Retrieved on: 
Wednesday, March 10, 2021

Parkinson's disease is a progressive neurodegenerative disease with the prevalence of one in 100 people over the age of 60, or around five million people worldwide.

Key Points: 
  • Parkinson's disease is a progressive neurodegenerative disease with the prevalence of one in 100 people over the age of 60, or around five million people worldwide.
  • Of these patients, almost all receive levodopa (also known as L-Dopa), a dopamine precursor that enables patients to reinitiate normal movement.
  • Levodopa-induced dyskinesia occurs with an average latency of around six years and affects 95% of all patients within 15 years of chronic L-Dopa treatment.
  • Valence's AI-enabled drug design platform has been extensively validated and is currently being used to identify and design drug candidates in collaboration with industry-leading partners.